Literature DB >> 23328676

Role of rho-kinase gene polymorphisms and protein expressions in colorectal cancer development.

Ibrahim Sari1, Betul Berberoglu, Esma Ozkara, Serdar Oztuzcu, Celaletdin Camci, Abdullah T Demiryurek.   

Abstract

OBJECTIVE: The aim of this study was to investigate a possible association between Rho-kinase (ROCK1 and ROCK2) gene polymorphisms and colorectal cancer (CRC) development.
METHODS: Eighty-five patients operated due to CRC and 178 healthy controls with similar age and sex were included to this study. Genomic DNA from the patients and the healthy control cases was analyzed by a BioMark 96.96 dynamic array system. The protein expressions of ROCK1, ROCK2 and p53 were determined by immunohistochemical staining.
RESULTS: There were significant associations between ROCK1 (rs73963110 and rs35996865) and ROCK2 gene polymorphisms (rs2290156, rs10178332, rs35768389, rs10929732 and rs34945852) with CRC development. However, no marked associations were found between ROCK2 gene rs965665, rs2230774, rs6755196 and rs1515219 polymorphisms and the risk of developing CRC. Rho-kinase and p53 immunohistochemical stainings were markedly elevated in the tumor tissue. There were significant correlations between vascular and perineural invasions with ROCK2 or p53 protein expressions.
CONCLUSIONS: These results are the first to demonstrate the contribution of Rho-kinase in CRC development in patients. Our data showed that the ROCK1 and ROCK2 genes might be a risk factor for CRC development and that genetic polymorphisms in these genes may modify individual susceptibility to CRC in the Turkish population.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23328676     DOI: 10.1159/000341395

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  8 in total

1.  Association of Rho-kinase 1 (ROCK1) gene polymorphisms with Behçet's disease.

Authors:  Elif Oguz; Abdullah Tuncay Demiryürek; Yavuz Pehlivan; Bünyamin Kisacik; Esma Ozkara; Serdar Oztuzcu; Belgin Alasehirli; Ahmet Mesut Onat
Journal:  Mol Diagn Ther       Date:  2014-08       Impact factor: 4.074

2.  MicroRNA-126 inhibits tumor cell invasion and metastasis by downregulating ROCK1 in renal cell carcinoma.

Authors:  Gui-Ming Zhang; Lei Luo; Xue-Mei Ding; Da-Hai Dong; Bin Li; Xiao-Cheng Ma; Li-Jiang Sun
Journal:  Mol Med Rep       Date:  2016-04-22       Impact factor: 2.952

3.  Investigation of Rho-Kinase Expressions and Polymorphisms in Mantle Cell Lymphoma Patients.

Authors:  Didar Yanardağ Açık; Mehmet Yılmaz; İbrahim Sarı; Serdar Öztuzcu; Zeynel A Sayıner; Salih Subari; Abdullah T Demiryürek
Journal:  Turk J Haematol       Date:  2015-08-06       Impact factor: 1.831

Review 4.  Novel Insights into the Roles of Rho Kinase in Cancer.

Authors:  Lei Wei; Michelle Surma; Stephanie Shi; Nathan Lambert-Cheatham; Jianjian Shi
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-01-02       Impact factor: 4.291

5.  Linkage analysis revealed risk loci on 6p21 and 18p11.2-q11.2 in familial colon and rectal cancer, respectively.

Authors:  Susanna von Holst; Xiang Jiao; Wen Liu; Vinaykumar Kontham; Jessada Thutkawkorapin; Jenny Ringdahl; Patrick Bryant; Annika Lindblom
Journal:  Eur J Hum Genet       Date:  2019-04-05       Impact factor: 4.246

Review 6.  Rho-Kinase as a Target for Cancer Therapy and Its Immunotherapeutic Potential.

Authors:  Seohyun Kim; Seong A Kim; Jihoon Han; In-San Kim
Journal:  Int J Mol Sci       Date:  2021-11-29       Impact factor: 5.923

7.  ROCK2 Polymorphism and Expression Contribute to Increased Susceptibility and Poor Prognosis in Hepatocellular Carcinoma.

Authors:  Lifeng Qin; Xin Liu; Li'na Lan; Xiaoping Lv
Journal:  Int J Gen Med       Date:  2022-02-09

8.  Determining association of rho kinase 1 gene polymorphisms with risk of Alzheimer's disease: a multicenter pilot study.

Authors:  Ying Gao; Xia Li; Xiao-Hong Liu; Qian-Hua Zhao; Xiang-Qian Che; Qi-Hao Guo; Ru-Jing Ren; Gang Wang
Journal:  Ann Transl Med       Date:  2018-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.